<DOC>
	<DOCNO>NCT00867438</DOCNO>
	<brief_summary>The objective study evaluate efficacy tolerability oral parnaparin sodium ( 210mg ) , administer extended-release tablet identify CB-01-05-MMX™ .</brief_summary>
	<brief_title>Efficacy Tolerability New Oral Extended-Release Formulation Containing Parnaparin Sodium , Administered Add-on Therapy</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>1 . Male female patient , 18 70 year age . 2 . Patients confirm diagnosis ulcerative colitis treatment fixeddose oral mesalazine 5ASA derivative least 4 week high clinical suspicion active disease , confirm sigmoidoscopy enrolment study . 3 . Presence ulcerative colitis locate leave side colon , splenic flexure colon rectum ( 15 cm proximal anus ) . 4 . Patients mild moderate active ulcerative colitis , define DAI ≥ 4 ≤ 10 , CAI ≥ 5 ≤ 12 . 5 . Women negative serum test pregnancy . 6 . Women childbearing potential provide use adequate contraceptive precaution treatment period . Adequate contraceptive method define failure rate &lt; 1 % per year correctly use , include implant , injectables , combine oral pill , IUDs vasectomise partner stable relationship . 7 . Ability understand willing sign Informed Consent Form , document require read sign subject . 1 . Presence clinically significant medical condition determine Investigator . 2 . History hypersensitivity idiosyncratic reaction heparin . 3 . History hemorrhage , exclude intestinal bleeding due ulcerative colitis , hemocoagulative disorder , platelet dysfunction . 4 . Presence arterial hypertension ( SAP ≥ 160 mm Hg ; DAP ≥ 95 mm Hg ) . 5 . Receipt investigational agent within 90 day start treatment . 6 . Use rectal 5ASAs rectal corticosteroid within 2 week start study . 7 . Use antiTNF agent immunosuppressive drug azothioprine , 6mercaptopurine cyclosporine A last 3 month . 8 . Patients ulcerative colitis severe entity ( DAI &gt; 10 CAI &gt; 12 ) , limited distal ulcerative proctitis , infectious colitis confirm microbiological assessment stool . 9 . Patients severe intestinal bleeding , Hb &lt; 9 g/dL . 10 . Presence significant hepatic impairment ( AST , ALT &gt; 2 ULN ) . 11 . Presence significant renal impairment ( creatinine &gt; 2 ULN ) . 12 . Women pregnant breast feeding . 13 . Intestinal obstruction . 14 . Presence type 1 type 2 diabetes . 15 . Concomitant oral antibiotic treatment , within 2 week start study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>ulcerative colitis</keyword>
	<keyword>Left-sided , mild moderate ulcerative colitis</keyword>
</DOC>